Key Takeaways
- A reset year, as telegraphed: Revenue guided to INR3,400-3,500 crores and PAT to INR700-750 crores, roughly half the prior year's profit, driven by the end of the Revlimid exclusivity windfall.
- The base business must now carry the load: With no major first-to-file launches this year, earnings depend entirely on the base portfolio across India, U.S., Brazil, Canada, and South Africa.
- Diversification is the structural answer: The Adcock Ingram acquisition and growth in Brazil (expected to double to INR550-600 crores) and Crop Sciences (INR140 crores) are early steps in a deliberate shift to reduce dependence on U.S. one-offs.
- Cash is earmarked for M&A, not buybacks: Management explicitly ruled out buybacks, stating a preference to deploy cash on 1-2 large acquisitions outside India, with a deal hoped for in FY27.
- What to watch next quarter: Progress on closing an acquisition, the trajectory of the semaglutide launch in India, and any update on the Vizag FDA inspection.
The Revlimid Cliff & FY27 Reset
- The drop was expected: Management had guided for a decline, framing it as the natural cycle of a business built on one-off exclusivities; lenalidomide drove past earnings, and FY27 is the first year without it.
- PAT halves year-on-year: Profit after tax is guided to INR700-750 crores, down from approximately INR1,400 crores, as the high-margin exclusivity revenue rolls off completely.
- No new exclusivities to fill the gap in FY27: Management confirmed no exclusivities will contribute this year; the pipeline of first-to-file opportunities is built for FY28 and beyond. [5-6]
- Pomalidomide did not move the needle: The launch was competitive with 4-5 generics in the first wave despite namesake exclusivity, and revenue was not substantial.
- Other income provided a Q4 cushion: A surge in other income included licensing fees from the India launch of semaglutide and from foreign partners, but this is cyclical and event-dependent. [8-9]
Rajeev Nannapaneni: "I think you need to understand that the nature of this business is that you're going to have one-offs and then you're going to do very well at this time. And then when there's going to be a drop, you're going to have a year or 2 where you're going to see a dip."
Diversification: The Five-Country Base
- Earnings now come from five countries: India, U.S., Brazil, Canada, and South Africa (through associates) now contribute meaningfully, a shift from the earlier U.S.-only concentration that took years of investment to build.
- Brazil is the standout growth driver: Revenue is expected to jump from approximately INR280 crores to INR550-600 crores this year, described as "the biggest bump," driven by the oncology portfolio.
- Canada grows steadily: Expected to grow around 10-15%, with big launches timed for FY27-28, not FY26-27; semaglutide has not been filed there yet.
- South Africa entry via Adcock Ingram: The acquisition provides a number-two position in the market; current returns are slightly better than bank interest, with a target of 15-20% return on capital over time and a 3-4 year horizon before seeing full value.
- Crop Sciences gains traction: Revenue reached INR140 crores vs INR60 crores last year, driven by product launches, channel penetration, and people additions; the business is only 3-4 years into commercial presence and is being demerged for focused management.
- Agchem input costs are a near-term headwind: A 25-30% increase in raw material costs will impact the Crop Sciences division more than pharma because of higher domestic sales exposure; half of kharif procurement was done with preexisting inventory, partially managing the impact.
Rajeev Nannapaneni: "And in a competitive generic environment like ours, it's very difficult to grow organically. You have to grow inorganic. And unless you do these bold acquisitions, you'll not be able to acquire share and size and scale."
Pipeline: The Post-FY27 Promise
- Exclusivities return from FY28: Management stated that exclusivities will start kicking in post-FY27, with some triggered in FY27-28, and a "reasonable rise" expected from FY28 onwards. [5-6]
- Earnings compounding targeted at 15-25%: Starting from the FY27 base of INR700-750 crores, management expects more stable compounding growth for the next 2-3 years, driven by launches in Brazil and Canada across both FY27 and FY28.
- First-to-file engine is being rebuilt: The company is targeting another 8-9 U.S. filings next year, hoping for 1-2 complex first-to-files, and has built a pipeline for another 3-4 such opportunities over the next 7-8 years.
- The strategy is to invert the profit mix: Management's vision is for base revenue to contribute 70% of profit and first-to-file or special products to contribute 25-30%, reversing the historical ratio and reducing earnings volatility.
- Product details remain confidential: Management declined to name which exclusivities will trigger in which year or to split expected revenue contributions from specific country launches, citing confidentiality agreements.
Rajeev Nannapaneni: "I would want our base revenue to contribute 70% of our profit and the first to file or special product to contribute 25% to 30%. Earlier, the ratio was the other way around."
Capital Allocation: M&A Over Buybacks
- Buybacks are off the table: When asked directly, management gave a straight "No," stating a personal belief that cash should be used for acquisitions that deliver better long-term returns.
- 1-2 large acquisitions are the priority: Management is actively shopping and hoping to close something in FY27, working on a couple of transactions, with a preference for targets outside India where valuations are more reasonable.
- Adcock Ingram stake may increase: Over time, management hopes to increase its shareholding in the South African associate as and when the major shareholder provides an opportunity.
- The rationale is scale and stability: Management argued that in a competitive generic environment, organic growth alone is insufficient, and bold acquisitions are necessary to build a more diversified global company with less volatile earnings over the next five years.
Operational Updates
- Semaglutide India launch is underway: The vial was launched on day one and is doing better than the pen, which launched a month later due to logistics; the vial market is price-sensitive at under INR1,000 versus INR3,000-4,000 for the pen; annualized expectation is INR75-100 crores.
- U.S. FDA facility status is largely clean: Three of four facilities (Kothur formulation, Chennai API, Mekaguda API) were inspected in 2025 and cleared with EIRs; Vizag is the only pending inspection, expected anytime this year.
- R&D spend stays elevated: Budgeted at 7-9% of revenue for next year, already factored into the PAT guidance, with higher R&D and engineering write-downs of around INR20-30 crores impacting Q4 other expenses.
- Tax regime shift provides a one-time benefit: The company elected to move to the new tax regime from FY26-27, resulting in a one-time deferred tax benefit of INR115 crores; the future tax rate will be around 25% including surcharge.
- eGenesis remains a binary moonshot: The genetically modified pig kidney transplant program has dosed two patients who did well for about six months; the company is now working on the right immunosuppression dose and also exploring liver applications; management called it a monumental achievement but stressed it is a binary event requiring patience over the next 12-18 months.
Rajeev Nannapaneni: "I think the scheme of things, if you just think that you're able to transplant an animal kidney and put that in a human and that human being is able to do well for a few months is an absolutely monumental thing."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue | INR3,400-3,500 crores | FY27 |
| FY27 PAT | INR700-750 crores (includes associate profit) | FY27 |
| South African associate revenue | $580-600 million | FY27 |
| South African associate PAT | $47-48 million (subject to exchange rate and war factors) | FY27 |
| Future tax rate | Around 25% including surcharge | From FY27 |
| R&D expenditure | 7-9% of revenue | FY27 |
| Semaglutide India revenue | INR75-100 crores annualized | FY27 |
| Brazil subsidiary revenue | Grow from ~INR280 crores to INR550-600 crores | FY27 |
| Canada subsidiary growth | 10-15% | FY27 |
| U.S. front-end business | Break even | FY27 |
| Earnings compounding | 15-25% annually | Starting FY28, for 2-3 years |
| Exclusivity launches | Begin contributing | FY28 onwards |
| U.S. ANDA filings | 8-9 filings, hoping for 1-2 complex first-to-files | FY27 |
| Acquisition | Close 1-2 large deals outside India | Hoped for in FY27 |
| Adcock Ingram return target | 15-20% return on capital | Over time (~3-4 years) |
| Crop Sciences demerger | Complete separation for focused management | In process |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated net revenue | ₹816.9 cr, vs ₹1,287.3 cr in Q4 FY25 |
| Consolidated net profit (incl. associates) | ₹269 cr, vs ₹406 cr in Q4 FY25 |
| Onetime tax benefit | ₹115 cr, from remeasurement of deferred tax assets on move to new tax regime |
| FY27 revenue guidance | ₹3,400 cr to ₹3,500 cr |
| FY27 PAT guidance | ₹700 cr to ₹750 cr, includes associate profit |
| Adcock Ingram (associate) revenue | ₹1,208.2 cr, NATCO share of profit ₹35.7 cr |
| Adcock Ingram FY27 revenue guidance | $580 mn to $600 mn, PAT guidance $47 mn to $48 mn |
| Net cash (group level) | ₹2,400 cr |
| Full-year subsidiary sales | ₹730 cr |
| Brazil subsidiary turnover | ₹257 cr, plus ~₹30 cr direct billing from India |
| Canada subsidiary turnover | ₹229 cr |
| Crop Health Sciences revenue | ₹140 cr (FY26), vs ₹60 cr prior year |
| Semaglutide India monthly run rate | ₹2 cr (own brand), ₹4–5 cr including partners |
| Semaglutide India annualized expectation | ₹75 cr to ₹100 cr |
| R&D and engineering write-down | ₹20 cr to ₹30 cr in other expenses |
| U.S. filings completed in FY26 | 7 to 8 filings |
| Future tax rate (new regime) | ~25%, including surcharge |
| Brazil FY27 revenue expectation | ₹550 cr to ₹600 cr |
| Canada FY27 growth expectation | 10% to 15% |
| Agchem raw material cost increase | 25% to 30% |